Japan Cancer Research
World Leader in Particle Therapy & Precision Cancer Surgery
Particle Therapy Centers
Most in the world
Stomach Cancer Survival
Highest globally
Carbon Ion Power
vs. standard radiation
World Leader in Proton & Heavy Ion Therapy
Japan operates 25+ particle therapy centers (proton and carbon ion), more than any country globally. Carbon ion therapy offers 3x more precise tumor destruction than standard radiation.
Impact:
Treating cancers previously considered inoperable with minimal side effects
Stomach Cancer Treatment Excellence
Japan achieves 70%+ 5-year survival rates for stomach cancer (vs 35% globally) through early endoscopic detection, advanced surgical techniques, and targeted therapies.
Impact:
Highest stomach cancer survival rates worldwide
Revolutionary Cancer Vaccine Platform (Personalised Peptide Vaccine)
Japanese researchers developed personalized cancer vaccines using patient-specific tumor peptides, showing 2x survival improvement for advanced cancers.
Impact:
Custom vaccines for late-stage cancer patients
Robotic Surgery Innovation (da Vinci & Hinotori)
Japan leads Asia in robotic cancer surgery adoption and developed its own surgical robot (Hinotori) competing with da Vinci, performing 20,000+ procedures annually.
Impact:
More precise surgery with faster recovery times
Cancer & Aging Research Integration
Japan's unique aging population (29% over 65) provides unparalleled data on cancer in elderly patients, developing age-appropriate treatment protocols.
Impact:
Optimizing cancer treatment for aging populations globally
Liquid Biopsy Technology (Circulating Tumor DNA)
Japanese companies commercialized ultra-sensitive liquid biopsy tests detecting cancer DNA at 1-in-100,000 sensitivity, FDA-approved for US market.
Impact:
Catching cancer recurrence months earlier
Minimally Invasive Endoscopic Surgery
Japan pioneered endoscopic submucosal dissection (ESD) allowing removal of early-stage stomach/esophageal cancers without major surgery, now global standard.
Impact:
Curing early cancer without surgery
Cancer Drug Discovery (Antibody-Drug Conjugates)
Japanese pharma (Daiichi Sankyo) developed Enhertu, a breakthrough antibody-drug conjugate now FDA-approved for breast/lung cancer with 50%+ response rates.
Impact:
Revolutionizing targeted cancer therapy globally
National Cancer Center Japan
Tokyo
Japan's premier comprehensive cancer center. World leader in stomach cancer treatment, early detection, and minimally invasive surgery. Over 13,000 patients annually.
Key Specialties:
University of Tokyo Hospital
Tokyo
Top-ranked academic medical center. Pioneer in robotic surgery, cancer immunotherapy, and precision medicine for Japanese populations.
Key Specialties:
Osaka University Hospital
Osaka
Leading research in cancer vaccines, CAR-T therapy, and particle therapy. Strong international collaborations.
Key Specialties:
Kyoto University Hospital
Kyoto
Nobel Prize-winning institution (iPSCs). Cancer stem cell research, regenerative oncology, and innovative surgical techniques.
Key Specialties:
Japan welcomes international patients to cutting-edge clinical trials
Personalized Peptide Cancer Vaccine
Custom vaccines made from each patient's tumor peptides for advanced gastric, colorectal, and lung cancers showing significant survival benefit.
Carbon Ion Therapy for Pancreatic Cancer
Heavy ion (carbon) radiotherapy for inoperable pancreatic cancer, delivering 3x more powerful radiation than standard treatment.
Next-Gen CAR-T for Solid Tumors
Japanese-developed CAR-T cells engineered to penetrate solid tumors (stomach, esophageal, liver cancers common in Japan).
AI-Powered Endoscopic Detection
Real-time AI detecting early stomach and colon cancers during endoscopy with 95%+ accuracy, deployed across Japan.
Registry-listed trials for Japan currently tracked in our database, sourced from public trial registries.